Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide versus liraglutide added to insulin glargine in type 2 diabetes
2012-000027-40Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lixisenatide and liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in postprandial plasma glucose AUC after standardized breakfast. Started Mar 2012; status: completed.
02
Drugs
lixisenatideliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-000027-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000027-40.